2008年第3版NCCN—NHL指南更新解读——滤泡性淋巴瘤
被引量：1
摘要
近年来，滤泡性淋巴瘤（FL）患者的预后有了明显改善，2008年第3版NCCN—NHL诊治指南FL部分在基本保持2007年版原貌的基础上，主要在以下方面作了更新。
出处
《白血病．淋巴瘤》
CAS
2009年第8期494-495,508,共3页
Journal of Leukemia & Lymphoma
参考文献16
-
1Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst, 2007, 99: 706-714.
-
2Cheung MC, Haynes AE, Meyer RM, et al. Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario. Cancer Treat Rev, 2007, 33: 161-176.
-
3Canioni D, Salles G, Mounier N, et al. High numbers of tumorassociated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trail. J Clin Oncol, 2008, 26: 440-446.
-
4Hirt C, Schuler F, Kiefer T, et al. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t (14; 18) PCR monitoring in advanced stage follicular lymphoma patients. Br J Haematol, 2008, 141: 631-640.
-
5Pham RN, Goolev TA, Keenev GE, et al. The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma. Bone Marrow Transplant, 2007, 40: 1039-1044.
-
6Sebban C, Briee P, Delarue R, et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA Study. J Clin Oncol, 2008, 26: 3614-3620.
-
7Arcaini L, Montanari F, Alessandrino EP, et al. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oneol, 2008, 19: 1331-1335.
-
8Ladetto M, De Marco F, Benedetti F, et al. Prospective, muhicenter randomized GITMO/Ⅱ L trail comparing intensive (R-HDS) versus cochemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS dose not translate into an overall survival advantage. Blood, 2008, 111: 4004-4013.
-
9Vose JM, Bierman PJ, Loberiza FR, et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Bio Blood Marrow Transplant, 2008, 14: 36-42.
-
10Khouri IF, McLanghlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphosphamide, and rituximab. Blood, 2008, 111: 5530- 5536.
同被引文献7
-
1张之南,杨天楹.血液病学.北京:人民卫生出版社,2005:1249-1256.
-
2Gutierrez-Dekgado F, Maloney DG, Press OW, et al. Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant, 2001, 28: 455.
-
3Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med, 1997, 336: 1290-1297.
-
4Smith TJ, Hillner BE, Schmitz N, et al. Economic analysis of a randomized clinical trial to compare filgrasstim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non- Hodgkin's lymphoma. J Clin Oncol, 1997, 15: 5-10.
-
5Schmite N, Ddrger P, Zander AR, et al. Results of a randomised, controUed,multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant, 1995, 15: 261.
-
6Kewalramani T, Zelenetz AD, Hedrick EE, et al.High-does chemoradiotherapy and autologous stem cell transplantation for paitients with primary refractory aggressive non-Hodgkin's lymphoma: an intention-to-treat analysis. Blood, 2000, 96: 2399-2404.
-
7崔洪新,白波,陈维刚.自体造血干细胞移植治疗恶性淋巴瘤的研究进展[J].实用医药杂志,2004,21(2):168-169. 被引量：3
引证文献1
-
1陈波,王志国,肖亮,张颢,范艳玲,夏国强,邱林,展昭民,张伯龙,马军.自体造血干细胞移植治疗预后不良非霍奇金淋巴瘤的临床分析[J].白血病．淋巴瘤,2009,18(10):606-608.
-
1陈玉兰,李曙平,曾志坚.TPF诱导化疗序贯同步放化疗治疗局部晚期鼻咽癌患者疗效分析[J].内科,2017,12(2):185-187. 被引量：1
-
2宋腾,王华庆,张会来,钱正子,周世勇,邱立华,李兰芳,宋拯.改良国际预后指数(NCCN-IPI)对R-CHOP方案治疗弥漫大B细胞淋巴瘤的预后评估(附168例临床分析)[J].中国肿瘤临床,2015,42(21):1050-1055. 被引量：12
-
3康凯夫,王晓蔚,陈小伍,谭光明,康子婧.Beclin1在原发性肝细胞癌中的表达及其临床意义[J].南方医科大学学报,2009,29(1):151-153. 被引量：14
-
4王志刚,窦科峰,付由池,钱崇宽,黄汉涛.肝细胞癌和癌旁肝组织中转化生长因子β1表达与微血管密度的关系[J].西安交通大学学报（医学版）,2003,24(3):196-198.
-
5吴弘英,郝鲁梅,邢秀华,王雷,兰巧玲,马树沛.硼替佐米联合化疗治疗多发性骨髓瘤9例的临床分析[J].临床合理用药杂志,2009,2(16):63-64.
-
6许银实.肾细胞癌的CT征象与PCNA表达关系的研究[J].现代医药卫生,2009,25(12):1860-1861.
-
7刘卫平,王小沛,张晨,谢彦,林宁晶,涂梅峰,平凌燕,应志涛,邓丽娟,黄惠颖,吴梦,孙英丽,杜婷婷,冷馨,丁宁,郑文,宋玉琴,朱军.不同分层方法对早期弥漫大B细胞淋巴瘤预后价值的比较[J].中华血液学杂志,2016,37(4):269-272. 被引量：5
-
8吴标,黄诚,蒋侃,庄武,徐振武,张晶.培美曲塞治疗全身化疗和吉非替尼治疗失败的肺腺癌32例临床观察[J].中国肺癌杂志,2010,13(8):809-812. 被引量：11
-
9钟慧娟,许彭鹏,赵维莅.利妥昔单抗追加治疗对初次完全缓解的弥漫大B细胞淋巴瘤患者的疗效评估[J].中华血液学杂志,2016,37(9):756-761. 被引量：5
-
10王琰,杨晓煜.三氧化二砷联合低剂量沙利度胺治疗老年性多发性骨髓瘤临床观察[J].中国现代医学杂志,2014,24(6):86-88. 被引量：5
